Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

Hwang, G S; Bhat, R; Crutchley, R D; Trivedi, M V

Hwang, G S; Bhat, R; Crutchley, R D; Trivedi, M V.

Hwang GS; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Bhat R; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Crutchley RD; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
Trivedi MV; Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.

Pharmacogenomics J ; 18(2): 201-208, 2018 04.

Article en En | MEDLINE | ID: mdl-28762370

Asunto(s)

Antineoplásicos Hormonales/sangre; Neoplasias de la Mama/sangre; Neoplasias de la Mama/genética; Citocromo P-450 CYP2D6/genética; Polimorfismo Genético/genética; Tamoxifeno/análogos & derivados; Animales; Antineoplásicos Hormonales/uso terapéutico; Neoplasias de la Mama/tratamiento farmacológico; Femenino; Humanos; Tamoxifeno/sangre; Tamoxifeno/uso terapéutico; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Polimorfismo Genético / Tamoxifeno / Neoplasias de la Mama / Antineoplásicos Hormonales / Citocromo P-450 CYP2D6 Tipo de estudio: Prognostic_studies / Systematic_reviews Límite: Animals / Female / Humans Idioma: En Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google